MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

Summary

Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to pathogens including COVID-19.

Timeline

Start

2020-04-28

Primary completion

2023-01

Completion

2023-12

Drugs

Indications